Real-World FASENRA study completed in korea: safety under the microscope

NCT ID NCT05091333

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at the safety and effectiveness of FASENRA (benralizumab) in 51 Korean adults with severe eosinophilic asthma or eosinophilic granulomatosis with polyangiitis (EGPA). Researchers tracked side effects and how well the drug controlled symptoms during routine medical care. The goal was to confirm known safety information and catch any new issues.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FASENRA (benralizumab)
What this could lead to: If results confirm safety, it supports continued use of FASENRA for controlling severe asthma and EGPA in real-world settings.
What could go wrong: This is a small, observational postmarketing study (51 people) with no control group, so it cannot prove cause and effect or detect rare side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA, EGPA(EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma eosinophilic granulomatosis with polyangiitis T2-high asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTHMA, EGPA(EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS)

Contacts and locations

Locations

Research Site

Busan, South Korea
Research Site

Gangneung-si, South Korea
Research Site

Seoul, South Korea
Research Site

Suwon, South Korea
Research Site

Ulsan, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.